Abstract

Pilot Study of a Prototype Integrated Diabetes Management System and the Relationship of Use to Diabetes Management Behaviors and HbA1c Among Type 2 Diabetes Patients

Connor Devoe¹, BS; Nils Fischer¹, MPH; Tim Hale², PhD; Neda Derakhshani¹; Mursal Atif³; Harriett Gabbidon¹; Enrico Cagliero³, MD; Marie McDonnell⁴,⁵, MD; Kamal Jethwani⁶,⁷, MD, MPH

¹Partners HealthCare, Boston, MA, United States
²Department of Kinesiology and Community Health, University of Illinois, Urbana-Champaign, Urbana, IL, United States
³Diabetes Center, Massachusetts General Hospital, Boston, MA, United States
⁴Diabetes Center, Brigham and Women’s Hospital, Boston, MA, United States
⁵Diabetes Center, Brigham and Women’s Faulkner Hospital, Jamaica Plain, MA, United States
⁶Harvard Medical School, Boston, MA, United States
⁷Dermatology, Massachusetts General Hospital, Boston, MA, United States

Corresponding Author:
Connor Devoe, BS
Partners HealthCare
25 New Chardon Street
Boston, MA
United States
Phone: 603 748 1896
Email: cdevoe@bu.edu

Abstract

Background: Type 2 diabetes (T2D) is the seventh leading cause of death (2017) in the United States, and by 2030 it is estimated that it will affect 439 million globally. Effective glycemic control can be challenging for patients. A tool to guide patients’ in their self-management behaviors and share this data with their physician may improve insulin adherence leading to lower HbA₁c. We examined an integrated diabetes management (IDM) system that utilizes a Bluetooth-enabled insulin event capture device, a Bluetooth-enabled glucometer, and an Android smartphone app. IDM data can be viewed by clinicians in the electronic medical record (EMR).

Objective: The primary aim of this study is to describe how app use is related to insulin adherence, blood glucose measurements, meal snapshots, and step count. Secondarily, we assessed the impact on HbA₁c levels over a 3- and 6-month period.

Methods: Thirty-five participants were enrolled from Boston-area hospitals in this single-arm pilot study. Use of the IDM system was defined as the number of days per week participants logged into the app and moved past the home screen. Three app use groups were created: low app use (0.33-2.46 days per week), medium app use (2.54-5.08 days per week), and high app use (>5.4 days per week). Adherence to insulin, blood glucose measurements, and meal snapshots were defined as a ratio of actual weekly events recorded by participants’ app use divided by their physician’s recommendation. Step count was defined as the total weekly steps for each participant. Daily app-generated data on app use and indicators of diabetes management were collected. HbA₁c levels were assessed via blood test at enrollment, 3-months, and 6-months. Using a hierarchical linear mixed model, we examined changes in outcome measures while accounting for random intercepts and slopes to control for variation in individual outcomes over the study.

Results: Overall app use (average unique days using the app per week) declined from 6.19 days to 3.00 days (at 1 and 24 weeks, respectively). Participants with high app use had significant improvement in bolus and basal insulin adherence per week (0.009 \( P = 0.041 \) [95% CI 0.0004 to 0.018] and 0.016 \( P < 0.001 \) [95% CI 0.0079 to 0.023], respectively), but participants had no significant improvements in blood glucose and meal snapshot adherence or absolute step count. HbA₁c significantly decreased per week (coefficient –0.025 [95% CI –0.044 to –0.007], \( P = 0.007 \)) with an overall change of 0.6. Participants with high app use significantly improved their HbA₁c per week (–0.037 \( P = 0.016 \) [–0.066 to –0.0067]) compared to participants with medium and low app use, yielding a total improvement of 0.88 over 24 weeks.
Conclusions: Results show that bolus and basal insulin may have increased with higher app use. HbA1c significantly improved over the course of the study, along with significantly greater improvement in HbA1c among participants with higher app use compared to participants in the middle or low app use groups. This study is not designed or intended to evaluate efficacy but provides results to guide the future design and development of this prototype IDM system.

(iproc 2019;5(1):e16298) doi: 10.2196/16298

KEYWORDS
health behavior; type 2 diabetes mellitus; digital health; mobile app; IDM; patient engagement